Table of Contents

1. Introduction
   • Overview of Exciting Developments in the Medical Device Industry
   • Importance of Advancements for Global Healthcare
2. K-MEDI HUB’s Strategic Re-designation
   • K-MEDI HUB’s New Role with KOLAS
   • Implications for the Korean Medical Device Market
3. Breakthrough Product Launch by InBody
   • Introduction of “BWA ON” Home Water Meter
   • Impact on Lymphedema Management
4. Roen Surgical’s AI-based Kidney Stone Robot
   • Features of the Zamenix Surgical Robot
   • Potential Benefits for Kidney Stone Treatment
5. Ceragem’s Focus on Thermal Function in Massage Chairs
   • Innovations in the Pause M6 Massage Chair Collection
   • Significance of Thermal Technology in Massage Therapy
6. Osang Healthcare’s Blood Glucose Monitor Approval
   • Features of “GluNEO H” Blood Glucose Monitor
   • Expansion Plans and Impact on Diabetes Care
7. Industry Impact
   • Overall Influence of Recent Developments
   • Trends in Global Expansion and Innovation
8. Conclusion
   • Summary of Key Advances in the Medical Device Sector
   • Future Directions and Potential Challenges

Aesthetic Medical Device Firm AsteraSys Prepares for KOSDAQ Listing

AsteraSys, a company known for producing aesthetic medical devices, announced its intention to list on the KOSDAQ market by submitting a securities registration document to the Financial Supervisory Service. Established in 2015, AsteraSys has carved a niche in manufacturing and selling medical and beauty devices.

About AsteraSys and Its Market Strategy

AsteraSys specializes in aesthetic devices, with significant products like:

• High-Intensity Focused Ultrasound (HIFU) device, “Liftera”
• Monopolar Radio Frequency (RF) device, “Coolphases”

These devices leverage technology to offer non-invasive beauty treatments. AsteraSys has a robust global distribution network spanning 62 countries across Asia, South America, Europe, and the Middle East, expanding the reach of its innovative products.

Details on the Upcoming KOSDAQ Listing

AsteraSys plans to offer 3.65 million shares in this public offering. They have set the anticipated share price between 4,000 and 4,600 KRW. Consequently, the firm aims to raise a total of approximately 14.6 billion to 16.8 billion KRW through this listing.

Key Steps and Dates:

1. Demand Forecasting: Scheduled for November 25-29.
2. Public Subscription: Slated for December 4-5.
3. Listing Goal: December 2024.

The listing will be managed by a lead manager, DB Financial Investment.

Implications of the KOSDAQ Listing for AsteraSys

• Increased Capital: The capital raised will potentially accelerate AsteraSys’s R&D and marketing efforts, bolstering its international operations.
• Market Visibility: A KOSDAQ listing can heighten the company’s visibility, attracting more clients and investors.
• Competitive Edge: Provides financial stability, allowing AsteraSys to compete more fiercely in the medical device market.

Wrap-up

AsteraSys’s strategic move to list on KOSDAQ could mark a significant milestone in its growth journey. By raising capital through public investment, the company aims to enhance its market share and financial stability, ensuring its position as a leading player in the global aesthetic device industry.

Stay informed with Product Advisor and consider following AsteraSys’s progress as it approaches its anticipated December listing.